<code id='997CD22EB3'></code><style id='997CD22EB3'></style>
    • <acronym id='997CD22EB3'></acronym>
      <center id='997CD22EB3'><center id='997CD22EB3'><tfoot id='997CD22EB3'></tfoot></center><abbr id='997CD22EB3'><dir id='997CD22EB3'><tfoot id='997CD22EB3'></tfoot><noframes id='997CD22EB3'>

    • <optgroup id='997CD22EB3'><strike id='997CD22EB3'><sup id='997CD22EB3'></sup></strike><code id='997CD22EB3'></code></optgroup>
        1. <b id='997CD22EB3'><label id='997CD22EB3'><select id='997CD22EB3'><dt id='997CD22EB3'><span id='997CD22EB3'></span></dt></select></label></b><u id='997CD22EB3'></u>
          <i id='997CD22EB3'><strike id='997CD22EB3'><tt id='997CD22EB3'><pre id='997CD22EB3'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:1
          Balloon heart
          Adobe

          PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

          The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

          advertisement

          “We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          In Gaza, a nonprofit 3D prints tourniquets and stethoscopes
          In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

          Asidefromthestethoscope,thearound20-personGliateammanufacturestourniquets,earotoscopes,andcapstostop

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Explaining an after

          AdobeThisarticlewasadaptedfromSTAT’slatestreport,“Subgroupanalysis:howtoevaluateposthoctestsforsigni